Results 1 to 10 of about 12,197,984 (249)
Long acting growth hormone (LAGH), an update [PDF]
Frontiers in Pediatrics, 2023 In 1957, Maurice Raben at Yale was able to isolate and purify growth hormone from cadaveric pituitary glands. Pituitary growth hormone was the only way to treat children with growth hormone (GH) deficiency, until 1985 when recombinant GH became available
Margaret Steiner Grillo +2 more
doaj +8 more sources
Long‐acting growth hormone in 2022 [PDF]
Pediatric Investigation, 2023 After the isolation of pituitary growth hormone (GH) in 1957, this form of GH, always in limited supply, was the only drug available for the treatment of GH deficiency.
Margaret Steiner +2 more
doaj +4 more sources
Long-acting growth hormone for pediatric GHD: insights into molecular modification and clinical application [PDF]
Frontiers in EndocrinologyLong-acting growth hormone (LAGH) therapies represent a paradigm shift in the management of growth hormone deficiency (GHD), alleviating the burden of daily injections.
Jianyang Gu +3 more
doaj +6 more sources
Long‐Acting Growth Hormone Versus Daily Growth Hormone for Growth Hormone Deficiency Patients: A Network Meta‐Analysis of Clinical Trials [PDF]
Endocrinology, Diabetes & MetabolismIntroduction Current guidelines recognize daily recombinant human growth hormone (rhGH) as standard care and long‐acting growth hormone (LAGH) as an alternative for paediatric growth hormone deficiency (CHD).
Amir Abadi +8 more
doaj +3 more sources
Treatment with long-acting growth hormone: effectiveness and safety [PDF]
Frontiers in EndocrinologyLong-acting growth hormone (GH) formulations represent a clinically effective alternative to daily recombinant human GH (rhGH) administration, enabling extended dosing intervals and enhancing patient adherence. This approach is particularly beneficial in
Livia Basile +5 more
doaj +4 more sources
Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogs [PDF]
Frontiers in Endocrinology, 2021 Daily recombinant human GH (rhGH) is currently approved for use in children and adults with GH deficiency (GHD) in many countries with relatively few side-effects.
Kevin C. J. Yuen +3 more
doaj +5 more sources
Delphi-based Spanish consensus on the use of long-acting growth hormone in pediatric growth hormone deficiency: recommendations from the ConverGHe Working Group [PDF]
Frontiers in EndocrinologyBackgroundLong-acting growth hormone (LAGH) formulations have emerged as an alternative to daily recombinant human growth hormone (rhGH) in pediatric growth hormone deficiency (GHD).
Lidia Castro-Feijóo +5 more
doaj +4 more sources
What do we do now that the long-acting growth hormone is here? [PDF]
Frontiers in Endocrinology, 2022 In standard 52-week phase III clinical trials, once weekly lonapegsomatropin, somatrogon and somapacitan have been found to yield non-inferior height velocities and similar safety profiles to daily GH (DGH) in children with pediatric growth hormone ...
Bradley S. Miller
doaj +2 more sources
Pharmacological Research, 2023 We evaluated the efficacy, safety, adherence, quality of life (QoL) and cost-effectiveness of long-acting growth hormone (LAGH) vs daily growth hormone (GH) preparations in the treatment of growth hormone deficiency (GHD) in children. Systematic searches
Chiara Mameli +11 more
doaj +3 more sources
Frontiers in Endocrinology, 2021 BackgroundWe performed a meta-analysis to evaluate the efficacy and safety of weekly long-acting growth hormone replacement therapy compared to daily growth hormone in children with short stature.MethodsA systematic literature search up to April 2021 was
Liyan Ma +6 more
doaj +2 more sources